

ASX ANNOUNCEMENT

RESIGNATION OF DIRECTOR – DR MEL BRIDGES

Sydney Australia, 19 June 2014 The Board of Benitec Biopharma (ASX: BLT) (OTC: BTEBY) has today accepted the resignation of non-executive Director, Dr Melvyn Bridges. Dr Bridges has served on the Board since October 2007.

Benitec’s Chairman, Mr Peter Francis said, “Mel has been a key contributor in the transformation of Benitec over recent years. During Mel’s time on the Board, the company has transitioned from pre-clinical to clinical stage, increased its capitalisation to around \$150 million from \$15 million, established a broad program pipeline and entered the clinic with a first in man human trial in ddRNAi gene silencing in the US. Mel’s contribution to these outcomes has been significant.”

Dr Mel Bridges commented, “With the significant advances made recently, Benitec has matured to a well funded, stable, clinical stage company and I am proud to have played a part in its development. My resignation from the Benitec Board will allow me more time to focus on my Brisbane-based boards and personal business opportunities.”

The Directors and management of Benitec wish to publicly express their sincere appreciation to Mel for his wisdom, support and guidance over the past 7 years and wish him well in his future endeavours.

For further information, please contact the persons below, or visit the Benitec website at www.benitec.com.

<i>Company</i>	<i>Investor relations</i>
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: jlowe@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) (OTC Code: BTEBY) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington’s disease. For more information on Benitec refer to the Company’s website at www.benitec.com.